RU2014141362A - Комбинированная терапия пролиферативных нарушений - Google Patents
Комбинированная терапия пролиферативных нарушений Download PDFInfo
- Publication number
- RU2014141362A RU2014141362A RU2014141362A RU2014141362A RU2014141362A RU 2014141362 A RU2014141362 A RU 2014141362A RU 2014141362 A RU2014141362 A RU 2014141362A RU 2014141362 A RU2014141362 A RU 2014141362A RU 2014141362 A RU2014141362 A RU 2014141362A
- Authority
- RU
- Russia
- Prior art keywords
- day
- pharmaceutical product
- cancer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 title claims 3
- 238000002648 combination therapy Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 22
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract 21
- 150000003839 salts Chemical class 0.000 claims abstract 19
- 201000011510 cancer Diseases 0.000 claims abstract 15
- 239000000203 mixture Substances 0.000 claims abstract 14
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims abstract 10
- 229960003862 vemurafenib Drugs 0.000 claims abstract 10
- 239000013543 active substance Substances 0.000 claims abstract 8
- 230000035772 mutation Effects 0.000 claims abstract 8
- 229940083338 MDM2 inhibitor Drugs 0.000 claims abstract 6
- 239000012819 MDM2-Inhibitor Substances 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 206010009944 Colon cancer Diseases 0.000 claims abstract 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims abstract 4
- 206010039491 Sarcoma Diseases 0.000 claims abstract 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract 4
- 210000001072 colon Anatomy 0.000 claims abstract 4
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 4
- 201000001441 melanoma Diseases 0.000 claims abstract 4
- 206010038038 rectal cancer Diseases 0.000 claims abstract 4
- 201000001275 rectum cancer Diseases 0.000 claims abstract 4
- 201000002510 thyroid cancer Diseases 0.000 claims abstract 4
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612441P | 2012-03-19 | 2012-03-19 | |
| US61/612,441 | 2012-03-19 | ||
| PCT/EP2013/055522 WO2013139724A1 (en) | 2012-03-19 | 2013-03-18 | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014141362A true RU2014141362A (ru) | 2016-05-10 |
Family
ID=47884369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014141362A RU2014141362A (ru) | 2012-03-19 | 2013-03-18 | Комбинированная терапия пролиферативных нарушений |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9216170B2 (enExample) |
| EP (1) | EP2827859B1 (enExample) |
| JP (1) | JP6141958B2 (enExample) |
| KR (1) | KR101673731B1 (enExample) |
| CN (2) | CN104114168A (enExample) |
| AR (1) | AR090349A1 (enExample) |
| AU (1) | AU2013203637B2 (enExample) |
| BR (1) | BR112014018910A8 (enExample) |
| CA (1) | CA2861056A1 (enExample) |
| HK (1) | HK1201198A1 (enExample) |
| MX (1) | MX2014010590A (enExample) |
| NZ (1) | NZ626985A (enExample) |
| RU (1) | RU2014141362A (enExample) |
| SG (1) | SG11201404418QA (enExample) |
| WO (1) | WO2013139724A1 (enExample) |
| ZA (1) | ZA201405411B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| US20140200255A1 (en) | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
| US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| PT2884979T (pt) | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| MX393610B (es) * | 2013-11-11 | 2025-03-24 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| US20160303158A1 (en) * | 2013-12-05 | 2016-10-20 | Hoffmann-La Roche Inc. | Novel combination treatment for acute myeloid leukemia (aml) |
| US10227298B2 (en) * | 2014-04-15 | 2019-03-12 | Hoffmann-La Roche Inc. | Solid forms of a pharmaceutically active compound |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| CA2972076A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| EP3260119B1 (en) | 2015-02-20 | 2023-11-15 | Daiichi Sankyo Company, Limited | Combination method for treating cancer |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| WO2017066193A1 (en) * | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| KR20180093056A (ko) | 2015-12-14 | 2018-08-20 | 레드.컴, 엘엘씨 | 모듈형 디지털 카메라 및 셀룰러 폰 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN110585433A (zh) * | 2019-09-27 | 2019-12-20 | 青岛大学 | Braf-v600e的抑制剂的应用及用于治疗甲状腺癌的药物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
| PL1893612T3 (pl) | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| EP2130822A1 (en) | 2005-12-01 | 2009-12-09 | F. Hoffmann-La Roche AG | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| MY160737A (en) | 2009-04-03 | 2017-03-15 | Hoffmann La Roche | Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| EP2470898A4 (en) | 2009-08-24 | 2013-03-13 | Genentech Inc | DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS |
| US8779150B2 (en) | 2010-07-21 | 2014-07-15 | Hoffmann-La Roche Inc. | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| RS56759B2 (sr) | 2011-04-01 | 2024-10-31 | Genentech Inc | Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima |
| JP6251682B2 (ja) | 2011-10-28 | 2017-12-20 | ジェネンテック， インコーポレイテッド | メラノーマ治療の治療の組み合わせ及び方法 |
| US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
-
2013
- 2013-02-05 US US13/759,458 patent/US9216170B2/en active Active
- 2013-03-15 AR ARP130100844A patent/AR090349A1/es unknown
- 2013-03-18 KR KR1020147026040A patent/KR101673731B1/ko not_active Expired - Fee Related
- 2013-03-18 HK HK15101803.8A patent/HK1201198A1/xx unknown
- 2013-03-18 AU AU2013203637A patent/AU2013203637B2/en not_active Ceased
- 2013-03-18 CN CN201380009083.4A patent/CN104114168A/zh active Pending
- 2013-03-18 MX MX2014010590A patent/MX2014010590A/es unknown
- 2013-03-18 JP JP2015500865A patent/JP6141958B2/ja active Active
- 2013-03-18 CA CA2861056A patent/CA2861056A1/en not_active Abandoned
- 2013-03-18 EP EP13709468.6A patent/EP2827859B1/en active Active
- 2013-03-18 SG SG11201404418QA patent/SG11201404418QA/en unknown
- 2013-03-18 RU RU2014141362A patent/RU2014141362A/ru not_active Application Discontinuation
- 2013-03-18 CN CN201810155251.5A patent/CN108295063A/zh active Pending
- 2013-03-18 WO PCT/EP2013/055522 patent/WO2013139724A1/en not_active Ceased
- 2013-03-18 BR BR112014018910A patent/BR112014018910A8/pt not_active IP Right Cessation
- 2013-03-18 NZ NZ626985A patent/NZ626985A/en not_active IP Right Cessation
-
2014
- 2014-07-22 ZA ZA2014/05411A patent/ZA201405411B/en unknown
-
2015
- 2015-07-22 US US14/806,427 patent/US9486445B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140130179A (ko) | 2014-11-07 |
| AR090349A1 (es) | 2014-11-05 |
| US20130245039A1 (en) | 2013-09-19 |
| HK1201198A1 (en) | 2015-08-28 |
| BR112014018910A2 (enExample) | 2017-06-20 |
| CN104114168A (zh) | 2014-10-22 |
| CA2861056A1 (en) | 2013-09-26 |
| JP6141958B2 (ja) | 2017-06-07 |
| JP2015510908A (ja) | 2015-04-13 |
| US9486445B2 (en) | 2016-11-08 |
| US20160051525A1 (en) | 2016-02-25 |
| BR112014018910A8 (pt) | 2017-07-11 |
| WO2013139724A1 (en) | 2013-09-26 |
| SG11201404418QA (en) | 2014-10-30 |
| EP2827859A1 (en) | 2015-01-28 |
| ZA201405411B (en) | 2019-09-25 |
| MX2014010590A (es) | 2014-09-18 |
| CN108295063A (zh) | 2018-07-20 |
| NZ626985A (en) | 2016-07-29 |
| AU2013203637B2 (en) | 2016-07-07 |
| US9216170B2 (en) | 2015-12-22 |
| EP2827859B1 (en) | 2018-10-17 |
| AU2013203637A1 (en) | 2013-10-03 |
| KR101673731B1 (ko) | 2016-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2356547C2 (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2014119713A (ru) | Комбинирование лечения рака | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| RU2010151952A (ru) | Водорастворимые аналоги ацетаминофена | |
| RU2013110124A (ru) | Комбинированная противораковая терапия | |
| RU2014122154A (ru) | Композиции, пригодные для лечения вирусных заболеваний | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| JP2019511526A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| RU2600793C2 (ru) | Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида | |
| EA201201414A8 (ru) | КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ | |
| EA201300420A1 (ru) | Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид | |
| RU2014150860A (ru) | Режим дозирования pi-3 киназы | |
| RU2014129508A (ru) | Новая комбинация | |
| RU2013130926A (ru) | Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака | |
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| RU2013114400A (ru) | Способ и композиция для лечения рака | |
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180109 |